Kim Jun Yup, Bae Hee-Joon
Department of Neurology, Stroke Center, Seoul National University Bundang Hospital, College of Medicine, Seoul National University, Seongnam, Korea.
J Stroke. 2017 Jan;19(1):28-39. doi: 10.5853/jos.2016.01935. Epub 2016 Jan 31.
Spontaneous non-traumatic intracerebral hemorrhage (ICH) remains a significant cause of mortality and morbidity throughout the world. To improve the devastating course of ICH, various clinical trials for medical and surgical interventions have been conducted in the last 10 years. Recent large-scale clinical trials have reported that early intensive blood pressure reduction can be a safe and feasible strategy for ICH, and have suggested a safe target range for systolic blood pressure. While new medical therapies associated with warfarin and non-vitamin K antagonist oral anticoagulants have been developed to treat ICH, recent trials have not been able to demonstrate the overall beneficial effects of surgical intervention on mortality and functional outcomes. However, some patients with ICH may benefit from surgical management in specific clinical contexts and/or at specific times. Furthermore, clinical trials for minimally invasive surgical evacuation methods are ongoing and may provide positive evidence. Upon understanding the current guidelines for the management of ICH, clinicians can administer appropriate treatment and attempt to improve the clinical outcome of ICH. The purpose of this review is to help in the decision-making of the medical and surgical management of ICH.
自发性非创伤性脑出血(ICH)仍是全球范围内死亡率和致残率的重要原因。为改善脑出血的严重病程,过去10年开展了各种针对药物和手术干预的临床试验。近期大规模临床试验报告称,早期强化降压对脑出血可能是一种安全可行的策略,并提出了收缩压的安全目标范围。虽然已研发出与华法林和非维生素K拮抗剂口服抗凝药相关的新药物疗法来治疗脑出血,但近期试验未能证明手术干预对死亡率和功能结局的总体有益效果。然而,一些脑出血患者在特定临床背景和/或特定时间可能从手术治疗中获益。此外,微创外科血肿清除方法的临床试验正在进行,可能会提供阳性证据。在了解当前脑出血管理指南后,临床医生可以进行适当治疗,并尝试改善脑出血的临床结局。本综述的目的是帮助进行脑出血药物和手术治疗的决策。